340B Prime Vendor Program, managed by Apexus, and the Hemophilia Alliance announced today an innovative collaborative effort to assist participating federally funded hemophilia treatment centers.

IRVING, Texas/ Lansdale, Pa (January 14, 2010) – The 340B Prime Vendor Program, managed by Apexus, and  the Hemophilia Alliance announced today an innovative collaborative effort to assist participating federally funded hemophilia treatment centers in maximizing the benefits of 340B Drug Pricing Program and Prime Vendor Program discounts.  The two organizations are working together to assure that covered entities serving the hemophilia community have access to the best possible products and pricing. The collaborative partnership became effective January 1, 2010.  “We are excited about this collaboration because it enables us to significantly expand upon the current value the Prime Vendor is delivering to our participants serving the hemophilia community.  Hemophilia is a very specialized area and it made sense for both organizations to work together in serving their common customers.” said Chris Hatwig, Vice President of Apexus.  Mark Plencner, Chairperson of the Hemophilia Alliance stated “this collaboration gives both organizations the ability to think globally but act locally and keep the focus on delivering outstanding patient care.”